Biodexa Enters Into Exclusive License To eRapa, A Phase 3 Ready Asset For The Treatment Of Familial Adenomatous Polyposis; Worldwide Rights Come With $17M In Non-Dilutive Grant Funding For Pivotal Phase 3 Trial In FAP
Portfolio Pulse from Benzinga Newsdesk
Biodexa Pharmaceuticals PLC has entered into an exclusive worldwide license with Rapamycin Holdings Inc. (Emtora Biosciences) for eRapa, a Phase 3 ready asset for treating Familial Adenomatous Polyposis (FAP). The deal includes $17 million in non-dilutive grant funding from the Cancer Prevention and Research Institute of Texas for a pivotal Phase 3 trial. eRapa, a proprietary oral tablet formulation of rapamycin, aims to delay or prevent surgery in FAP patients and has potential in other cancers. Phase 2 results are expected in Q2 ‘24, with ongoing studies in bladder cancer.
April 26, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biodexa Pharmaceuticals PLC acquires exclusive worldwide rights to eRapa, a Phase 3 ready treatment for FAP, with $17M in grant funding for trials. This acquisition could significantly enhance Biodexa's oncology pipeline and stakeholder value.
The acquisition of eRapa not only strengthens Biodexa's position in the oncology market but also comes with substantial non-dilutive funding, which is likely to positively impact its financial health and stock price in the short term. The potential of eRapa in treating FAP and other cancers, along with the upcoming Phase 2 results, could serve as significant valuation catalysts for Biodexa.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100